Stock 300584 NANJING HICIN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Company Nanjing Hicin Pharmaceutical Co., Ltd.

Equities

300584

CNE100002F44

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 12/05/2024 BST 		5-day change 1st Jan Change
18.54 CNY +0.27% Intraday chart for Nanjing Hicin Pharmaceutical Co., Ltd. +0.82% -20.36%
04-24 Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
2023 Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI

Business Summary

Nanjing Hicin Pharmaceutical Co Ltd is a pharmaceutical company engaged in research, development and production of chemical preparations, active pharmaceutical ingredients and intermediates. The Company's primary products are torsemide for injection, tigecycline for injection, cefoxitin sodium for injection, cefotiam for injection and omeprazole sodium for injection. The torsemide for injection is a loop diuretic. The tigecycline for injection is an intravenous administrated glycyrrhizin antibiotic for the treatment of complex skin and skin structure infections or complex intra-abdominal infections. The cefoxitin sodium for injection is a cephalosporin antibiotic used for the treatment of respiratory, urinary and gastrointestinal infections. Its products cover a range of therapeutic areas, including diuresis, cardiovascular, anti-infection, digestive system, immune regulation, hypoglycemic and orthopedics.

Number of employees: 549

Sales per Business

CNY in Million2022Weight2023Weight Delta
Cardiovascular
69.4 %
210 39.8 % 360 69.4 % +71.50%
Antibiotics
12.3 %
73 13.8 % 64 12.3 % -12.21%
Diuretics
7.9 %
125 23.8 % 41 7.9 % -67.42%
Other
4.1 %
29 5.5 % 21 4.1 % -27.31%
Anti-virus
2.6 %
21 3.9 % 13 2.6 % -35.00%
Digestive
2.1 %
20 3.9 % 11 2.1 % -46.52%
Active Pharmaceutical Ingredients and Intermediates
0.7 %
38 7.3 % 3 0.7 % -91.15%
Immunomodulatory
0.6 %
6 1.2 % 3 0.6 % -54.77%
Other Business
0.4 %
4 0.7 % 2 0.4 % -50.28%

Sales per region

CNY in Million2022Weight2023Weight Delta
China
100.0 %
526 100.0 % 518 100.0 % -1.64%

Managers

Managers TitleAgeSince
Yu-Ping Cao CEO
 Chief Executive Officer 60 18/05/13
Mingsheng Feng BRD
 Director/Board Member 46 15/07/19
Fei Hua Zhang IRC
 Investor Relations Contact - -

Members of the board

Members of the board TitleAgeSince
Yu-Ping Cao CEO
 Chief Executive Officer 60 18/05/13
Xiang Li BRD
 Director/Board Member 47 15/07/19
Ling Xiao Mao BRD
 Director/Board Member 60 14/05/23
Ming Zhao BRD
 Director/Board Member 68 15/07/19
Mingsheng Feng BRD
 Director/Board Member 46 15/07/19
Yan Luo CHM
 Chairman 42 15/07/19
Li Ye Zhu BRD
 Director/Board Member 35 15/07/19

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 120,000,000 46,331,569 ( 38.61 %) 0 38.61 %

Shareholders

NameEquities%Valuation
GF Fund Management Co., Ltd.
0.004060 %
2,600 0.004060 % 6 470 ¥
Truvalue Asset Management Co. Ltd.
0.000625 %
400 0.000625 % 995 ¥
HuaAn Fund Management Co., Ltd.
0.000156 %
100 0.000156 % 249 ¥

Company contact information

Nanjing Hicin Pharmaceutical Co., Ltd.

Nanjing Eco & Tech Dev Zone 1 Hengfa Road

210046, Nanjing

+86 25 8322 2911

http://www.hicin.cn
address Nanjing Hicin Pharmaceutical Co., Ltd.(300584)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
NANJING HICIN PHARMACEUTICAL CO., LTD. Stock Nanjing Hicin Pharmaceutical Co., Ltd.
-20.36% 307M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+29.98% 684B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.34% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.52% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.59% 329B
ABBVIE INC. Stock AbbVie Inc.
+4.07% 284B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.21% 240B
NOVARTIS AG Stock Novartis AG
+9.66% 208B
ROCHE HOLDING AG Stock Roche Holding AG
-6.83% 200B
AMGEN INC. Stock Amgen Inc.
+7.09% 166B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 300584 Stock
  4. Company Nanjing Hicin Pharmaceutical Co., Ltd.